About Macular Edema
Macular edema results from fluid accumulation in the macular region of the retina. Macular edema arises from various etiologies such as diabetes, AMD, and RVO. Macular edema disrupts the central vision due to swelling of the macula. Currently, the treatment plan involves the use of surgical and laser therapies as well as drugs such as anti-VEGF therapies and NSAIDs. Surgery and laser therapy are intended to prevent further damage to vision. However, anti-VEGF therapies have been reported to improve the vision loss associated with macular edema.
TechNavio's analysts forecast the Global Macular Edema market will grow at a CAGR of 9.1 percent over the period 2014-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Macular Edema market for the period 2013-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat macular edema associated with distinct etiologies.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Macular Edema market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio's report, the Global Macular Edema Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Macular Edema market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Regeneron Pharmaceuticals Inc.
Other Prominent Vendors
• Alcon Inc.
• Alimera Sciences Inc.
• Allergan Inc.
• Ampio Pharmaceuticals Inc.
• iCo Therapeutics Inc.
• Pfizer Inc.
• Santen Pharmaceutical Co. Ltd.
Key Market Driver
• Increase in Patient Population
• For a full, detailed list, view our report.
Key Market Challenge
• Increasing Use of Off-label Drugs
• For a full, detailed list, view our report.
Key Market Trend
• Increasing Recommendations by NICE
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Disease Overview
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Market Analysis of Major Drugs
07.3.1 Lucentis
07.3.2 Eylea
07.4 Market Analysis of Other Prominent Drugs
07.4.1 Ozurdex
07.4.2 Iluvien
07.5 Five Forces Analysis
08. Market Segmentation by Molecule Type
08.1.1 Recombinant Protein
08.1.2 Small Molecule
09. Geographical Segmentation
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2013
17.3 Other Prominent Vendors and Future Vendors
18. Key Vendor Analysis
18.1 Bayer AG
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Segmentation
18.1.4 Business Segmentation by Revenue 2012 and 2013
18.1.5 Sales by Geography
18.1.6 Business Strategy
18.1.7 Key Information
18.1.8 SWOT Analysis
18.1.9 Strengths
18.1.10 Weaknesses
18.1.11 Opportunities
18.1.12 Threats
18.2 F. Hoffmann La Roche Ltd.
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Business Segmentation
18.2.4 Business Segmentation by Revenue 2012 and 2013
18.2.5 Sales by Geography
18.2.6 Business Strategy
18.2.7 Key Information
18.2.8 SWOT Analysis
18.2.9 Strengths
18.2.10 Weaknesses
18.2.11 Opportunities
18.2.12 Threats
18.3 Novartis AG
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Segmentation by Revenue 2013
18.3.4 Business Segmentation by Revenue 2012 and 2013
18.3.5 Sales by Geography
18.3.6 Business Strategy
18.3.7 Key Developments
18.3.8 SWOT Analysis
18.3.9 Strengths
18.3.10 Weaknesses
18.3.11 Opportunities
18.3.12 Threats
18.4 Regeneron Pharmaceuticals Inc.
18.4.1 Key Facts
18.4.2 Business Overview
18.4.3 Product Segmentation
18.4.4 Revenue Product Segmentation
18.4.5 Business Strategy
18.4.6 Key Information
18.4.7 SWOT Analysis
18.4.8 Strengths
18.4.9 Weaknesses
18.4.10 Opportunities
18.4.11 Threats
19. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Macular Edema Market 2013-2018 (US$ billion)
Exhibit 3: Timeline of Key Regulatory Approvals of Lucentis
Exhibit 4: Geography-wise Segmentation of Lucentis Sales (US$ million)
Exhibit 5: Lucentis' Revenue 2006-2013 (US$ million)
Exhibit 6: Timeline of Key Regulatory Approvals and Filings of Eylea
Exhibit 7: Geography-wise Segmentation of Eylea Sales (US$ million)
Exhibit 8: Eylea's Revenue 2011-2013 (US$ million)
Exhibit 9: Global Macular Edema Market Segmentation by Molecule Type
Exhibit 10: Global Macular Edema Market by Geographical Segmentation 2013
Exhibit 11: Global Macular Edema Market Share Analysis 2013
Exhibit 12: Bayer AG: Business Segmentation 2013
Exhibit 13: Bayer AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 14: Bayer AG: Sales by Geography 2013
Exhibit 15: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 16: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
Exhibit 17: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 18: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
Exhibit 19: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 20: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 21: Novartis AG: Sales by Geography 2013
Exhibit 22: Regeneron Pharmaceuticals Inc.: Product Segmentation
Exhibit 23: Regeneron Pharmaceuticals Inc.: Revenue Product Segmentation 2013
